Cumulative Days of Musculoskeletal Improvement in Bio-Naïve Patients With PsA With or Without Metabolic Syndrome and Obesity Receiving Risankizumab Through Week 244: Integrated Results From the KEEPsAKE Clinical Trials (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1310; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; No abstract available
Clinical • Genetic Disorders • Metabolic Disorders • Musculoskeletal Diseases • Obesity
|
|
Saakshi Khattri, MD; MBBS
|